Michael R. Page, PharmD, RPh
The ATS 2013 conference focused on pulmonary care, critical care, sleep medicine, and more.
Kristen Harrison, MPH; Frederick Brown, PharmD; Brandeis Seymore, RPh; Anthony Palmieri, PharmD, MBA; Olga S. Matlin, PhD; and Steven M. Kymes, PhD
We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.
From the Editor
Jan E. Berger, MD, MJâ€”Editor-in-Chief
Physicians should work with retail pharmacies to find cost-effective medication strategies for their patients.
Xiaoyun Pan, PhD and Usha Sambamoorthi, PhD
Using the SEER-Medicare database, we found negative association between Medicare claim processors“related physician's chemotherapy reimbursement and their prescription of granulocyte colony-stimulating factor for non-Hodgkin lymphoma patients.
Myrl Weinberg, FASAE, CAE
A tool for organizing patient concerns and comments to ensure that the FDA captures the comprehensive information it needs to integrate patient perspectives throughout the agency's review process.
Specialty Healthcare Benefits Council
Ken S. Latta, RPh, BS; Gregory S. Burger, RPh, MS; and James A. Jorgenson, RPh, MS
With increasing regulatory oversight for sterile compounding and a limited ability to assure the quality of compounded sterile products obtained from external sources, many hospital pharmacies are moving to insource these products.
Vanja Sikirica, PharmD, MPH; Jipan Xie, MD, PhD; Tony Lizhang He, BS; M. Haim Erder, PhD; Paul Hodgkins, PhD, MSc; Hongbo Yang, PhD; Thomas Samuelson, BA; and Eric Q. Wu, PhD
Treatment patterns, resource utilization, and healthcare costs associated with guanfacine immediate release versus guanfacine extended release were compared in children and adolescents with attention-deficit/hyperactivity disorder.
Berhanu Alemayehu, DrPH; Joseph A. Crawley, MS; Xiongkan Ke, MS; and Marta Illueca, MD
Healthcare utilization and costs for patients taking esomeprazole were compared in the 12-month periods before and after exclusion of the proton pump inhibitor from formulary.
Kimberly A. Burns, RPh, JD; Janene M. Madras, BS Pharm, PharmD, BCPS, BCACP; Mary E. Ray, BS Pharm, PharmD; Daniel P. Oâ€™Neil, PharmD; Andrew L. Bruinsma, PharmD; Emily Ferrare, PharmD, MS, RD, LDN; and Michael M. Madden, PhD
This study evaluated the categories, quantities, and prescribers of unused first-fill medications returned through a Drug Enforcement Administration National Drug Take-Back Day event.